Literature DB >> 6249763

Long-term T-cell-mediated immunity to Epstein-Barr virus in man. IV. Development of T-cell memory in convalescent infectious mononucleosis patients.

A B Rickinson, D J Moss, J H Pope, N Ahlberg.   

Abstract

Under appropriate culture conditions, EB virus infection of lymphocytes from seropositive donors leads to regression of transformation, and this was shown previously to be due to activation in a secondary immune response to T lymphocytes inhibitory for the autologous lymphoblastoid cell line. Regression can be quantified by determining the number of cells required for its expression. To investigate the development of memory T cells with EB-virus specificity in the primary infection, a comparison was made of the capacity for regression of lymphocytes from 16 cases of infectious mononucleosis (IM) and 13 normal donors. With 9 normal seropositive donors a mean lymphocyte concentration of 4.6 X 10(5)/ml was required to achieve 50% regression. In contrast, with 8 cases of IM tested within 1 week of onset, a much higher mean lymphocyte concentration (3.7 X 10(6)/ml) was necessary. Six of these IM cases, and another not tested in the first week, were tested on several occasions between 5 and 23 weeks after onset, and showed a slight reduction in the mean cell concentration required for regression (1.5 X 10(6)/ml). Six additional were tested 23--83 weeks after onset by which time the cell concentration required for 50% regression (mean = 4.5 X 10(5)/ml) had reached the level shown by normal seropositive donors. Regression did not occur with lymphocytes from seronegative donors, even at the highest cell concentration. Recombination cultures of T-cell-depleted and T-cell-enriched lymphocyte populations from 3 IM cases in ratios of 1:7 to 7:1 showed that the failure of regression in acute IM was not due simply to lack of sufficient numbers of T cells. The results indicate that EB-virus-specific memory T-cell activity as detected by the regression test is absent in the acute phase of IM, becomes evident at low levels 5--23 weeks after onset, and reaches a maximum after about 6 months.

Entities:  

Mesh:

Year:  1980        PMID: 6249763     DOI: 10.1002/ijc.2910250108

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4+ T cells.

Authors:  Jinjong Myoung; Don Ganem
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

2.  Demonstration in vitro of cell mediated immunity to Epstein-Barr virus in cotton-top tamarins.

Authors:  S Finerty; F T Scullion; A J Morgan
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

3.  Stress, loneliness, and changes in herpesvirus latency.

Authors:  R Glaser; J K Kiecolt-Glaser; C E Speicher; J E Holliday
Journal:  J Behav Med       Date:  1985-09

4.  Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.

Authors:  R J Tierney; N Steven; L S Young; A B Rickinson
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

5.  HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus.

Authors:  I S Misko; D J Moss; J H Pope
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

6.  Evidence for disregulation in the control of Epstein-Barr virus latency in patients with AIDS-related complex.

Authors:  G Ragona; M C Sirianni; S Soddu; B Vercelli; G Sebastiani; M Piccoli; F Aiuti
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

7.  Serum fatty acid proportions are altered during the year following acute Epstein-Barr virus infection.

Authors:  L L Williams; D M Doody; L A Horrocks
Journal:  Lipids       Date:  1988-10       Impact factor: 1.880

8.  In vitro analysis of Epstein-Barr virus: host balance in patients with acute Plasmodium falciparum malaria. I. Defective T-cell control.

Authors:  D E Gunapala; C A Facer; R Davidson; W R Weir
Journal:  Parasitol Res       Date:  1990       Impact factor: 2.289

9.  Epstein-Barr virus antibodies in patients with ataxia-telangiectasia and other immunodeficiency diseases.

Authors:  J H Joncas; A Wills; E Reece; Z Fox
Journal:  Can Med Assoc J       Date:  1981-10-15       Impact factor: 8.262

10.  Epstein-Barr virus-specific cytotoxic T cell responses in rheumatoid arthritis patients.

Authors:  J S Gaston; A B Rickinson; M A Epstein
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.